ArticlePediatric quality & safety
Impact of a Quality Improvement Initiative to Reduce Medication-induced Kidney Injury.
Article in Pediatric quality & safety. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute kidney injury (AKI) is a common complication of nephrotoxic medication use in hospitalized children. Prior studies have shown that the use of electronic health record alerts to identify patients exposed to nephrotoxic medications reduced exposure and the incidence of AKI. This initiative aimed to reduce the incidence of AKI by implementing a process to identify nephrotoxic exposures and standardize care for patients receiving nephrotoxic medications. Methods: We used quality improvement methodology to identify and reduce nephrotoxic medication exposure and to standardize hydration and monitoring for patients receiving them. We tested the process on a single hospital service before expanding to other services, with ongoing optimization via monthly Plan-Do-Study-Act cycles. Results: During the 48-month study period, we observed a significant decrease in the mean number of patients exposed to nephrotoxic medications, from a baseline of 11.3 patients per 1,000 patient-days per month to 6.6 patients per 1,000 patient-days per month, a 42% decrease. For patients exposed to nephrotoxic medications, there was an increase in AKI monitoring (via increased creatinine testing) and an increase in the percentage who developed AKI. Conclusions: We adapted and implemented a screening process for exposure to nephrotoxic medications, along with a novel hydration and monitoring pathway. Consistent with previous studies, we observed a dramatic decrease in exposure. An increase in the detection of AKI and a reduction in the proportion of lower risk patients may explain the unexpected increase in the percentage who developed AKI. Our study suggests that implementing standardized identification and monitoring processes can reduce exposure, and that automation and adherence monitoring are important for demonstrating reductions in AKI.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.